IL273994A - Combined treatment with PARP inhibitor and PD-1 antagonist - Google Patents

Combined treatment with PARP inhibitor and PD-1 antagonist

Info

Publication number
IL273994A
IL273994A IL273994A IL27399420A IL273994A IL 273994 A IL273994 A IL 273994A IL 273994 A IL273994 A IL 273994A IL 27399420 A IL27399420 A IL 27399420A IL 273994 A IL273994 A IL 273994A
Authority
IL
Israel
Prior art keywords
combination
binding antagonist
axis binding
parp inhibitor
parp
Prior art date
Application number
IL273994A
Other languages
English (en)
Hebrew (he)
Inventor
Andrew Blake-Haskins John
Hendrik Boshoff Christoffel
Cesari Rossano
Serge Antoine Nuyten Dimitry
Anthony Stewart Ross
ZOHREN Fabian
Original Assignee
Pfizer
Merck Patent Gmbh
John Andrew Blake Haskins
Hendrik Boshoff Christoffel
Cesari Rossano
Serge Antoine Nuyten Dimitry
Anthony Stewart Ross
ZOHREN Fabian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Merck Patent Gmbh, John Andrew Blake Haskins, Hendrik Boshoff Christoffel, Cesari Rossano, Serge Antoine Nuyten Dimitry, Anthony Stewart Ross, ZOHREN Fabian filed Critical Pfizer
Publication of IL273994A publication Critical patent/IL273994A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL273994A 2017-10-13 2020-04-16 Combined treatment with PARP inhibitor and PD-1 antagonist IL273994A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572024P 2017-10-13 2017-10-13
US201862697587P 2018-07-13 2018-07-13
PCT/US2018/055174 WO2019075032A1 (en) 2017-10-13 2018-10-10 COMBINATION OF A PARP INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST

Publications (1)

Publication Number Publication Date
IL273994A true IL273994A (en) 2020-05-31

Family

ID=64049735

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273994A IL273994A (en) 2017-10-13 2020-04-16 Combined treatment with PARP inhibitor and PD-1 antagonist

Country Status (13)

Country Link
US (1) US20200254091A1 (enExample)
EP (1) EP3694551A1 (enExample)
JP (1) JP2020536887A (enExample)
KR (1) KR20200071097A (enExample)
CN (1) CN111225685A (enExample)
AU (1) AU2018347331A1 (enExample)
BR (1) BR112020006371A2 (enExample)
CA (1) CA3078806A1 (enExample)
IL (1) IL273994A (enExample)
MX (1) MX2020003361A (enExample)
RU (1) RU2020113246A (enExample)
TW (1) TW201922288A (enExample)
WO (1) WO2019075032A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190062515A (ko) * 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
CN113116881B (zh) * 2019-12-31 2025-03-07 甫康（上海）健康科技有限责任公司 一种用于治疗肿瘤的药物组合及其应用
JP2023524270A (ja) * 2020-05-04 2023-06-09 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｄ－１アンタゴニスト、化学放射線療法およびｐａｒｐ阻害剤の組み合わせを用いた癌の治療方法
WO2022200982A1 (en) * 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN104478875B (zh) 2008-08-06 2017-04-12 麦迪韦逊科技有限公司 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
EP2531033A4 (en) 2010-02-03 2013-07-31 Biomarin Pharm Inc POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES
KR101826652B1 (ko) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
KR20190120458A (ko) 2010-10-21 2019-10-23 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN105916846A (zh) 2013-11-07 2016-08-31 麦迪韦逊科技有限公司 用于合成经保护的n-烷基三唑甲醛的三唑中间体
PL3102605T3 (pl) * 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
EP3563870A1 (en) * 2014-07-15 2019-11-06 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
CN107206088A (zh) * 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
RU2714233C2 (ru) * 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
MX2017015937A (es) * 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
SG11201803462PA (en) 2015-10-26 2018-05-30 Medivation Tech Llc Treatment of small cell lung cancer with a parp inhibitor

Also Published As

Publication number Publication date
AU2018347331A1 (en) 2020-04-09
RU2020113246A (ru) 2021-11-15
BR112020006371A2 (pt) 2020-09-29
WO2019075032A1 (en) 2019-04-18
EP3694551A1 (en) 2020-08-19
JP2020536887A (ja) 2020-12-17
RU2020113246A3 (enExample) 2021-11-15
MX2020003361A (es) 2020-07-29
KR20200071097A (ko) 2020-06-18
US20200254091A1 (en) 2020-08-13
CA3078806A1 (en) 2019-04-18
TW201922288A (zh) 2019-06-16
CN111225685A (zh) 2020-06-02

Similar Documents

Publication Publication Date Title
IL273994A (en) Combined treatment with PARP inhibitor and PD-1 antagonist
IL287518A (en) Dual inhibitors of the vista and pd-1 pathways
IL279991A (en) PD-1/PD-L1 inhibitors
IL262814B1 (en) Combination treatments of hdac inhibitors and pd-l inhibitors
IL256775A (en) Combination of a pd-1 antagonist with an egfr inhibitor
IL247102B1 (en) Combination of pd-1 antagonist and ido1 inhibitor for cancer treatment
SG11202106304RA (en) Irreversible inhibitors of menin-mll interaction
LT3612525T (lt) Pd-1/pd-l1 inhibitoriai
PT3752501T (pt) Inibidores de pd-1/pd-l1
IL287959A (en) Dual inhibitors of the tim-3 and pd-1 pathways
IL288467A (en) Preparation of a parp inhibitor pill and a method for its preparation
IL268981B1 (en) Solid forms and combined preparations containing beta-lactamase inhibitor and uses thereof
IL259857A (en) Combined treatment with a pd-1 signal inhibitor
IL285927A (en) Combinations of rad51 and parp inhibitors
LT3700902T (lt) Trpc6 inhibitoriai
IL275331A (en) Quinazolinones as PARP14 inhibitors
PT3621694T (pt) Inibidores de lrrc33 e sua utilização
PT3380456T (pt) Complexo de antagonista de recetor de angiotensina e inibidor de endopeptidase neutro.
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
SG10202103332UA (en) Solid forms of ttk inhibitor
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases